SBP GROUP (01177.HK): Establishes Joint Venture with Indonesia’s Tempo Scan Holding 51% Stake to Expand Innovative Drug Market in Southeast Asia
NewTimeSpace News: On 27 July 2026, Sino Biopharmaceutical Limited (01177.HK) issued a voluntary announcement stating that the Group has entered into a joint venture agreement with PT Tempo Scan Pacific Tbk of Indonesia to set up PT TEMPO CTTQ BIOPHARMACEUTICAL INDONESIA (TCBI). Sino Biopharmaceutical will hold a 51% stake while Tempo Scan holds the remaining 49%.
The joint venture will leverage the Group’s strengths in innovative R&D and product pipeline, together with Tempo Scan’s local capabilities including manufacturing, regulatory registration, market access and nationwide distribution network in Indonesia.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
- SBP GROUP (01177.HK): TQ-A3334 20.8% HBsAg clearance at week 48
- SBP GROUP (01177.HK): Boehringer deal worth up to US$7bn
- SBP GROUP (01177.HK): Two Hepatitis B Drugs Granted CDE Breakthrough Therapy Status
- SBP GROUP (01177.HK): TQB2102 Data at ESMO; Phase III Breast Cancer Median PFS 16.4 Months
- SBP GROUP (01177.HK): TQC2731 Phase III fully enrolled in CRSwNP